- Home
- ABTS vs VIVS Comparison
ABTS vs VIVS Comparison
Compare ABTS & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- VIVS
- Stock Information
- Founded
- ABTS 2010
- VIVS 2007
- Country
- ABTS Hong Kong
- VIVS United States
- Employees
- ABTS N/A
- VIVS N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABTS Technology
- VIVS Health Care
- Exchange
- ABTS Nasdaq
- VIVS Nasdaq
- Market Cap
- ABTS 8.9M
- VIVS 8.1M
- IPO Year
- ABTS N/A
- VIVS N/A
- Fundamental
- Price
- ABTS $6.11
- VIVS $2.25
- Analyst Decision
- ABTS
- VIVS
- Analyst Count
- ABTS 0
- VIVS 0
- Target Price
- ABTS N/A
- VIVS N/A
- AVG Volume (30 Days)
- ABTS 57.2K
- VIVS 1.4M
- Earning Date
- ABTS 08-13-2025
- VIVS 11-06-2025
- Dividend Yield
- ABTS N/A
- VIVS N/A
- EPS Growth
- ABTS N/A
- VIVS N/A
- EPS
- ABTS N/A
- VIVS N/A
- Revenue
- ABTS $7,037,156.00
- VIVS $140,000.00
- Revenue This Year
- ABTS N/A
- VIVS $42.38
- Revenue Next Year
- ABTS N/A
- VIVS $15.42
- P/E Ratio
- ABTS N/A
- VIVS N/A
- Revenue Growth
- ABTS 31.69
- VIVS 35.92
- 52 Week Low
- ABTS $1.35
- VIVS $1.41
- 52 Week High
- ABTS $14.10
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ABTS 44.85
- VIVS 45.97
- Support Level
- ABTS $5.80
- VIVS $2.02
- Resistance Level
- ABTS $6.61
- VIVS $2.36
- Average True Range (ATR)
- ABTS 0.52
- VIVS 0.29
- MACD
- ABTS -0.06
- VIVS 0.01
- Stochastic Oscillator
- ABTS 28.18
- VIVS 23.64
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.